Peptides for Heart Health: What the Research Shows

Key Takeaways

• What this covers: The natriuretic peptide family (ANP, BNP, CNP) as endogenous cardiac regulators and clinical biomarkers; GLP-1 receptor agonists with FDA-approved cardiovascular indication data; food-derived antihypertensive peptides; and research-phase compounds studied for cardiac protection.
• FDA-approved context: BNP as nesiritide (Natrecor) was FDA-approved in 2001 for acute decompensated heart failure but has since been discontinued from active U.S. marketing by its manufacturer. Semaglutide (Wegovy) received an FDA-approved indication in 2024 for cardiovascular risk reduction in adults with established CVD and overweight/obesity. Tirzepatide is FDA-approved for type 2 diabetes and chronic weight management; its cardiovascular outcome trial (SURPASS-CVOT) is ongoing and no CV indication is approved.
• Research-phase compounds: BPC-157 has animal model cardiac data only; no human cardiovascular trials have been published as of April 2026. BPC-157 is not on the FDA 503A positive bulks list and FDA has stated it does not support 503A compounding of this substance pending further review (status subject to change).
• Evidence stage: Natriuretic peptides: extensive human clinical trial and guideline-level evidence. GLP-1 class: multiple Phase 3 cardiovascular outcome trials (semaglutide only has an FDA-approved CV indication). Research compounds: animal model data only for cardiac indications.
• No peptide is currently FDA-approved for primary prevention of cardiovascular disease in the general adult population. Nesiritide is approved for treatment of acute decompensated heart failure (discontinued in active marketing). Semaglutide (Wegovy) is approved for cardiovascular risk reduction as secondary prevention in adults with established cardiovascular disease and overweight/obesity. All other peptide cardiovascular applications — including GLP-1 agents used for CV risk reduction outside their specific approved populations, and research compounds like BPC-157 — are investigational, observational, or off-label.

Peptides the Heart Already Makes

Before discussing research-phase compounds, it is worth establishing what is already known: the heart is itself a peptide-producing organ. The natriuretic peptide family is the most important example, and its members have become both clinical biomarkers and approved therapeutic agents — a trajectory that illustrates both the promise and the complexity of peptide cardiovascular medicine.

The natriuretic peptide family: ANP, BNP, and CNP

A comprehensive 2020 review by Goetze and colleagues in Nature Reviews Cardiology described the synthesis, secretion, and physiological roles of the cardiac natriuretic peptide family in detail, establishing the foundational reference [review]. Three peptides constitute this family, each with distinct tissue origins and functional profiles.

Atrial natriuretic peptide (ANP) is produced primarily by the atria in response to atrial stretch from volume overload. It acts on the kidneys to increase sodium and water excretion (natriuresis and diuresis), relaxes vascular smooth muscle to reduce blood pressure, and counteracts the renin-angiotensin-aldosterone system. B-type natriuretic peptide (BNP) is produced by the ventricles under conditions of increased ventricular wall stress — pressure overload or volume overload — and has the same downstream effects as ANP, but its ventricular origin makes it more specifically sensitive to heart failure. A 2021 review by Kuwahara in Pharmacology and Therapeutics detailed the natriuretic peptide system in heart failure, including diagnostic and therapeutic implications [review]. A 2024 clinical review by Shalmi and colleagues in Advances in Clinical Chemistry provided an updated reference on natriuretic peptide measurement and clinical interpretation [review of clinical practice].

C-type natriuretic peptide (CNP) operates differently from ANP and BNP. Rather than acting as a circulating endocrine hormone, CNP functions primarily as a paracrine regulator in vascular and cardiac tissue. A 2019 review by Moyes and colleagues in the International Journal of Molecular Sciences established CNP's role as a paracrine regulator of vasculature and heart through local cGMP-mediated signaling distinct from the endocrine ANP/BNP pathway [review]. A 2024 review by Dickinson and colleagues in Pharmacology and Therapeutics covered CNP's cardiovascular and systemic actions in detail, including its emerging role in bone growth regulation and vascular protection [review].

Why natriuretic peptide deficiency matters

The significance of these endogenous peptides is not just that they are diagnostic markers — they are physiologically essential for cardiac stability. A 2022 study by Hall and colleagues in Cardiovascular Research demonstrated that natriuretic peptide deficiency sensitizes the heart to stress-induced ventricular arrhythmias in animal models, illustrating why maintaining adequate natriuretic peptide signaling has direct cardiac electrical stability implications [animal model]. A 2024 study by Giovou and colleagues in Cells examined how natriuretic peptides regulate cardiac homeostasis and mediate responses to cardiac disease across the developmental and adult heart [review and mechanistic data].

How Natriuretic Peptides Are Used in Clinical Practice

Natriuretic peptides have two clinical applications: as diagnostic and prognostic biomarkers, and as therapeutic agents. These are well-established, guideline-supported applications based on large human trial datasets — not investigational research.

As biomarkers: NT-proBNP and BNP in heart failure

NT-proBNP (N-terminal pro-B-type natriuretic peptide) and BNP are the most widely used cardiac peptide biomarkers in clinical medicine. Elevated levels indicate increased ventricular wall stress, which occurs in heart failure, left ventricular dysfunction, and conditions that increase cardiac loading. A 2023 scientific statement by Tsutsui and colleagues in the European Journal of Heart Failure established natriuretic peptides as cornerstones of heart failure diagnosis and management, with guideline-level endorsement from the Heart Failure Society of America, the European Society of Cardiology, and the Japanese Heart Failure Society [clinical guideline]. A companion statement by Tsutsui and colleagues in the Journal of Cardiac Failure provided additional guideline context for natriuretic peptides in heart failure management [clinical guideline]. BNP is not exclusive to left heart failure: a 2004 paper by Yap and colleagues in Chest documented that natriuretic peptide elevation also occurs in respiratory disease and right heart dysfunction, which is clinically important for correct interpretation [human observational]. A 2022 study by Miyoshi and colleagues in Pediatric International demonstrated that natriuretic peptides predict neonatal heart failure, showing that clinical utility extends across the lifespan [human study].

As therapeutic agents: nesiritide and emerging peptide drugs

Nesiritide (Natrecor) is recombinant human BNP that was FDA-approved in 2001 for acute decompensated heart failure. It was administered intravenously in hospital settings to reduce pulmonary capillary wedge pressure and improve dyspnea in acutely decompensated patients. Post-approval evidence (ASCEND-HF, 2011) tempered initial enthusiasm, and the product has since been discontinued from active U.S. marketing by its manufacturer (the FDA approval itself has not been withdrawn). A 2023 review by Sangaralingham and colleagues in Cardiovascular Research covered natriuretic peptide pathways in heart failure and emerging therapeutic possibilities including recombinant peptide drugs and enhanced peptide analogs in development [review]. Nesiritide represents a milestone case of a recombinant cardiac peptide receiving FDA approval with Phase 3 clinical trial data, rather than a currently prescribable U.S. product.

GLP-1 Receptor Agonists and Cardiovascular Outcomes

The FDA-approved GLP-1 receptor agonist class represents the other major category of peptide-based cardiovascular medicine. These are prescription medications — not research compounds — with large-scale cardiovascular outcome trial data.

Cardiovascular outcomes data for approved GLP-1 agents

A 2025 review by Liu and colleagues in Drug Design, Development and Therapy reviewed clinical applications of GLP-1 receptor agonists and GLP-1/GIP dual agonists including cardiovascular outcomes across completed major trials [review of human RCT data]. Semaglutide demonstrated MACE reduction in specific high-risk populations — adults with type 2 diabetes and high CV risk (SUSTAIN-6) and adults with established CVD and overweight/obesity without diabetes (SELECT). Semaglutide (Wegovy) received an FDA-approved indication in March 2024 for cardiovascular risk reduction in adults with established CVD and overweight/obesity, based on the SELECT trial. Tirzepatide does not currently have an FDA-approved cardiovascular indication; its cardiovascular outcome trial (SURPASS-CVOT) is ongoing as of April 2026. A 2026 review by Khan and colleagues in the European Heart Journal reviewed anti-obesity medications in cardiovascular disease prevention, including GLP-1 agents and their emerging role in cardiovascular medicine [review]. A 2025 review by Petsas and colleagues in Molecules examined protein-ligand interactions in cardiometabolic drug targets, framing the proposed mechanistic basis for cardiovascular effects observed in some weight-management peptide classes [review].

Semaglutide (brand Wegovy, with an FDA-approved CV risk reduction indication in adults with established CVD and overweight/obesity) and tirzepatide (brand Mounjaro/Zepbound, FDA-approved for type 2 diabetes and chronic weight management, without an approved CV indication) are available through licensed providers as FDA-approved prescription medications. Compounded versions of semaglutide and tirzepatide are a separate regulatory category and are not FDA-approved; following the resolution of the 2023–2024 GLP-1 drug shortage in 2024–early 2025, compounding of these molecules is subject to the standard 503A bulks and clinical difference requirements, and the regulatory landscape for compounded GLP-1 products continues to evolve. Their cardiovascular evidence base is categorically different from any research peptide discussed below.

Food-Derived Peptides and Blood Pressure

A third category of peptide-cardiovascular science involves bioactive sequences released naturally from food proteins during digestion. These are not pharmaceutical compounds or supplements but rather dietary components with documented biochemical activity relevant to blood pressure regulation.

ACE-inhibiting food peptides

Angiotensin-converting enzyme (ACE) converts angiotensin I to angiotensin II, which raises blood pressure through vasoconstriction and aldosterone-mediated sodium retention. Certain peptide fragments released during digestion of dairy casein, fish proteins, and legumes inhibit ACE activity, producing a mild antihypertensive effect. A 2025 review by Guo and colleagues in Food Chemistry reviewed food-derived bioactive sequences with ACE-inhibition mechanisms, documenting the breadth of food sources and the specificity of identified peptide sequences [review]. A 2021 review by Liao and colleagues in Critical Reviews in Food Science and Nutrition covered the ACE2/Angiotensin(1-7)/MasR axis as an emerging antihypertensive peptide target, extending beyond classic ACE inhibition to the newer counter-regulatory arm of the renin-angiotensin system [review]. A 2024 review by Ichim and colleagues in Molecular Nutrition and Food Research evaluated the potential impact of bioactive food peptides in addressing hypertension, a primary heart disease risk factor [review of human and preclinical data]. These are dietary mechanisms, not therapeutic claims; the effect sizes from food-derived peptides are modest compared to pharmaceutical ACE inhibitors.

Research-Phase Compounds: BPC-157 and Cardiovascular Models

Beyond the FDA-approved natriuretic peptide and GLP-1 categories, one research compound has been specifically studied in animal cardiac models: BPC-157.

BPC-157 in cardiac disturbance models

BPC-157 is a synthetic pentadecapeptide. As of April 2026, BPC-157 is not on the FDA 503A positive bulks list; FDA has stated it does not support 503A compounding of this substance pending further agency review. No FDA-approved BPC-157 drug product exists, and this regulatory status is subject to change. A 2022 review by Sikiric and colleagues in Biomedicines described BPC-157 as a cytoprotective compound studied in heart disturbance applications, including arrhythmia and vascular injury models in animals [review of animal data]. The proposed mechanisms include NO-system modulation, growth factor upregulation, and cytoprotection pathways consistent with BPC-157's broader documented profile in other organ systems. No controlled human trials of BPC-157 for any cardiovascular indication have been published as of April 2026. The animal model data is hypothesis-generating. Superpower does not prescribe, sell, compound, or facilitate access to BPC-157 for any indication, including cardiac.

What the Research Shows: Evidence-Level Summary

• Natriuretic peptides (ANP, BNP, CNP — endogenous and as nesiritide)
  • Volume of evidence: Extensive human clinical trial and guideline data
  • Key finding: BNP/NT-proBNP are guideline-standard diagnostic markers; nesiritide (recombinant BNP) was FDA-approved in 2001 for acute decompensated heart failure but has since been discontinued from active U.S. marketing.
  • Strength of inference: Biomarker use (BNP/NT-proBNP for heart failure diagnosis and monitoring) — highest, with guideline-level support. Nesiritide as therapeutic — FDA-approved with Phase 3 trial evidence; post-approval ASCEND-HF evidence tempered clinical enthusiasm and the product has since been discontinued from active U.S. marketing.
• GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide)
  • Volume of evidence: Multiple completed Phase 3 cardiovascular outcome trials
  • Key finding: Semaglutide (Wegovy) has an FDA-approved indication (March 2024) for cardiovascular risk reduction in adults with established CVD and overweight/obesity, based on the SELECT trial (Lincoff et al., 2023, NEJM), which demonstrated statistically significant MACE reduction in the approved indication population. Tirzepatide and other GLP-1 agents do not currently have FDA-approved cardiovascular indications.
  • Strength of inference: Highest for semaglutide in its approved CV population — FDA-approved with Phase 3 cardiovascular outcome data
• Food-derived antihypertensive peptides
  • Volume of evidence: Moderate human observational and small RCT data
  • Key finding: ACE-inhibiting peptide sequences from dairy, fish, and legumes show modest blood pressure effects in dietary studies
  • Strength of inference: Moderate; effect sizes modest compared to pharmaceutical ACE inhibitors
• BPC-157 (research compound)
  • Volume of evidence: Animal models only for cardiac indications
  • Key finding: Cytoprotective effects in cardiac disturbance animal models; no human cardiac trials published
  • Strength of inference: Hypothesis-generating only; not established in humans

Safety Considerations

The safety profile across these categories varies enormously by compound and regulatory status. FDA-approved natriuretic peptides and GLP-1 agents have characterized safety profiles from large human trials. Research compounds have uncharacterized human safety for cardiac indications.

FDA-approved compounds: known profiles

Nesiritide's primary safety consideration is hypotension, which is managed by careful dosing titration in monitored hospital settings. GLP-1 receptor agonists' cardiovascular safety profile includes gastrointestinal adverse effects as the most common category; thyroid C-cell effects observed in rodent carcinogenicity studies are a subject of ongoing pharmacovigilance. Full prescribing information for these compounds is available at DailyMed.

Populations who should exercise caution with research compounds

The following clinical considerations are not medical advice; any peptide use in these populations requires direct clinician oversight:

• Individuals with active cardiovascular disease: Any research compound being considered alongside cardiac medications requires review by a cardiologist. The interaction between research peptides and cardiac drugs — including antiarrhythmics, anticoagulants, and vasodilators — has not been characterized in human trials.
• Individuals with heart failure: The natriuretic peptide system is already under pharmacological management in heart failure care. Uncharacterized interventions that affect volume status or vascular tone carry unpredictable consequences in this population.
• Individuals with hypertension on ACE inhibitors or ARBs: Compounds that additionally modulate the renin-angiotensin system (including food-derived ACE-inhibiting peptides at high intakes) may have additive effects on blood pressure that require monitoring.

What is not yet known

Long-term cardiac safety of BPC-157 in humans is uncharacterized. The interaction between GH-stimulating peptides and cardiac remodeling — growth hormone has known effects on cardiac structure and function — has not been formally studied in the context of the research-grade compounds commonly used in wellness contexts. Drug-peptide interactions for cardiac medications and research compounds are essentially unknown.

How to Access These Compounds

Nesiritide was FDA-approved in 2001 for acute decompensated heart failure but has been discontinued from active U.S. marketing — it is not currently a commercially available U.S. product. GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) are available by prescription through licensed healthcare providers; only semaglutide (Wegovy) has an FDA-approved cardiovascular risk reduction indication, in adults with established CVD and overweight/obesity. As of April 2026, BPC-157 is not on the FDA 503A positive bulks list, FDA has stated it does not support 503A compounding of this substance pending further review, and there is no FDA-approved BPC-157 drug product for cardiac indications. Superpower does not prescribe, sell, compound, or facilitate access to BPC-157 for any indication, including cardiovascular applications.

Which Biomarkers Are Relevant for Cardiovascular Health?

Understanding baseline cardiovascular biology provides the context for evaluating how any compound — FDA-approved or investigational — affects cardiac and vascular health. These markers represent the objective reference points that cardiovascular medicine uses to characterize risk, monitor disease, and evaluate treatment responses.

• NT-proBNP / BNP: The primary cardiac peptide biomarkers. Elevated levels indicate increased ventricular wall stress. A baseline value establishes cardiac status before any intervention. Superpower's cardiovascular health biomarker guide covers these markers in the context of a comprehensive cardiac workup.
• hs-CRP: Systemic inflammatory burden is one of the strongest independent predictors of major adverse cardiovascular events. Baseline hs-CRP provides a measurement of inflammatory cardiovascular risk that is independent of lipid levels.
• LDL cholesterol and ApoB: LDL-C and its protein carrier ApoB are the primary modifiable drivers of atherosclerotic cardiovascular disease. A baseline LDL cholesterol measurement is the starting point for assessing this risk. ApoB is increasingly preferred by cardiologists as a more precise indicator of atherogenic particle burden.
• Triglycerides: Elevated triglycerides are associated with increased cardiovascular risk, particularly in the context of insulin resistance. They are directly relevant to GLP-1 class compounds, which produce meaningful triglyceride reductions in clinical trials.
• HbA1c and fasting glucose: Metabolic cardiovascular risk is tightly coupled to insulin resistance and hyperglycemia. A baseline HbA1c characterizes long-term glucose control — one of the primary risk axes where GLP-1 receptor agonists demonstrate benefit.
• IGF-1: Growth hormone has well-documented effects on cardiac structure and function — both GH deficiency and excess are associated with cardiac remodeling. Baseline IGF-1 levels establish the GH axis status for anyone considering compounds that affect this system.

Whether you are evaluating an FDA-approved GLP-1 agent with your clinician, understanding the clinical significance of a BNP result, or simply wanting to understand your cardiovascular biology, establishing objective biomarker baselines is how clinical decisions become grounded in actual data. That approach is foundational to Superpower's approach to preventive health.